bis(furan-3-yl) ketone | 127158-63-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: bis(furan-3-yl) ketone
• 英文别名: di(3-furyl) ketone；di(furan-3-yl)methanone；di-(furan-3-yl)ketone；Di-(3-furyl)ketone；bis(furan-3-yl)methanone
• CAS: 127158-63-8
• 化学式: C₉H₆O₃
• 分子量: 162.145
• InChiKey: JPRNUCYAJLDDDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  242.4±15.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  bis(furan-3-yl) ketone 以 四氢呋喃 、 乙腈 为溶剂， 反应 4.0h， 生成 6,11-ethano-12,12-di(3'-furanyl)-6,11 dihydrobenzoquinolizinium perchlorate
  参考文献：
  名称：

  Discovery of 6,11-Ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium Cations, a Novel Class of N-Methyl-D-aspartate Antagonists

  摘要：

  6,11-Ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations 8, a novel class of N-methyl-D-aspartate (NMDA) antagonists acting at the phencyclidine site, have been identified. Structure-activity relationship studies around the lead compound 8a led to the identification of 12g (WIN 67870-2), one of the most potent compounds in this series. Compound 12g has a K-i = 1.8 +/- 0.2 nM vs [H-3]TCP binding, has 700-fold selectivity for binding to the open state of the NMDA receptor-ionophore, and was devoid of MK-801- and PCP-like behavioral effects in rats. Compound 12g was neuroprotective in cultured mouse cortical neurons and exhibited antiischemic activity in a rat middle cerebral artery occlusion/reperfusion model of focal ischemia.

  DOI：

  10.1021/jm00001a006
• 作为产物：
  描述：

  3-糠酸 在 4-二甲氨基吡啶 、 正丁基锂 、 氯化亚砜 、 ammonium chloride 作用下， 以 正己烷 、 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 bis(furan-3-yl) ketone
  参考文献：
  名称：

  Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and

  摘要：

  替代的6,11-乙烷-6,11-二氢苯并[b]喹啉盐，含有它们的药物组合物，以及利用它们治疗神经退行性疾病或神经毒性损伤的方法，其中替代的6,11-乙烷-6,11-二氢苯并[b]喹啉盐具有以下结构式：##STR1## 其中：R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、X 和 p 如规范中所定义。

  公开号：

  US05554620A1

文献信息

• Substituted heterocyclylisoquinolinium salts and compositions and method
  申请人：Sterling Winthrop Inc.

  公开号：US05569655A1

  公开（公告）日：1996-10-29

  Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  取代杂环异喹啉盐，含有它们的药物组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Synthesis of Symmetrical Diaryl Ketones by Cobalt-Catalyzed Reaction of Arylzinc Reagents with Ethyl Chloroformate
  作者：Alice Rérat、Christophe Michon、Francine Agbossou-Niedercorn、Corinne Gosmini

  DOI：10.1002/ejoc.201600738

  日期：2016.9

  Symmetrical diaryl ketones were prepared by a cross-coupling reaction between aryl bromides and ethyl chloroformate. This new method, which uses a catalyst composed of CoBr2 and a bipyridine ligand along with readily available starting materials, allows for the synthesis of a variety of symmetrical diaryl ketones in moderate to excellent yields (37–99 %) under mild conditions. This reaction, in which

  通过芳基溴化物和氯甲酸乙酯之间的交叉偶联反应制备对称二芳基酮。这种新方法使用由 CoBr2 和联吡啶配体组成的催化剂以及容易获得的起始材料，允许在温和条件下以中等至优异的产率 (37-99%) 合成各种对称的二芳基酮。在这种反应中，氯甲酸乙酯在钴和锌的存在下充当一氧化碳的替代物，代表了先前已知的二芳基甲酮合成方法的有趣替代方法。
• Regiospecific synthesis of 3,4-disubstituted furans and 3-substituted furans using 3,4-Bis(tri-n-butylstannyl)furan and 3-(tri-n-butylstannyl)f
  作者：Yun Yang、Henry N.C. Wong

  DOI：10.1016/s0040-4020(01)85528-9

  日期：1994.1

  3,4-Bis(tri-n-butylstannyl)furan and 3-(tri-n-butylstannyl)furan have been prepared and used successfully as building blocks to lead to various

  制备了3,4-双（三-正丁基锡烷基）呋喃和3-（三-正丁基锡烷基）呋喃，并成功地用作制造各种产品的基础。
• Substituted heterocyclylisoquinolinium salts and compositions and
  申请人：Sterling Winthrop Inc.

  公开号：US05604224A1

  公开（公告）日：1997-02-18

  Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  替代杂环异喹啉盐，含有它们的制药组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Substituted 6,11-ethano-6,11-dihydrobenzo[B]quinolizinium salts and
  申请人：Sanofi Winthrop, Inc.

  公开号：US05631264A1

  公开（公告）日：1997-05-20

  Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  该专利描述了6,11-乙烷基-6,11-二氢苯并[b]喹啉盐的替代物，含有它们的制药组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。